Axitinib
(AK-sih-TIH-nib) This page contains brief information about axitinib and a collection of links to more information about the use of this drug, research results, and ongoing clinical trials.
| US Brand Name(s): |  | Inlyta |
| | ||
| | ||
| FDA Approved: | | Yes |
Axitinib is approved to treat:
- Renal cell carcinoma (a type of kidney cancer) that is advanced. It is used in patients whose disease has not gotten better with other chemotherapy.
Axitinib is also being studied in the treatment of other types of cancer.
More About AxitinibDefinition from the NCI Drug Dictionary - Detailed scientific definition and other names for this drug.
Research ResultsNew Targeted Agent Shows Efficacy in Advanced Kidney Cancer - Information about the use of this drug to treat cancer.
Clinical Trials Accepting PatientsFind Clinical Trials for Axitinib - Check for trials from NCI's list of cancer clinical trials now accepting patients.
Important: The drug information on this page is meant to be educational. It is not a substitute for medical advice. The information may not cover all possible uses, actions, interactions, or side effects of this drug, or precautions to be taken while using it. Please see your health care professional for more information about your specific medical condition and the use of this drug.
Back to Top
